Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and utility of complex biomarkers have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L., Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G., Tafe, Laura J., Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M., Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944039/
https://www.ncbi.nlm.nih.gov/pubmed/29743104
http://dx.doi.org/10.1186/s40425-018-0344-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944039/
https://www.ncbi.nlm.nih.gov/pubmed/29743104
http://dx.doi.org/10.1186/s40425-018-0344-8

Ejemplares similares